ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Implementing plasma p-tau217 and cognitive testing for Alzheimer's screening in low-education populations in central China.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma GFAP modifies the association of depressive symptoms with cognitive function: A population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Review
- Anemia, iron deficiency, and blood biomarkers for Alzheimer disease: clinical interpretation and dementia risk stratification.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
introductionWe evaluated a pragmatic screening strategy combining brief cognitive assessment with plasma phosphorylated tau217 (p-tau217) in an elderly health screening cohort.
methodsParticipants completed the Memory and Executive Screening (MES) test and plasma biomarker assessment. Cognitive impairment was defined using individualized residual norms derived from an internal reference sample. The p-tau217 thresholds were positive predictive value (PPV) -oriented and anchored to age- and cognitive status-specific prior probabilities of amyloid-β (Aβ) pathology.
resultsMES-defined cognitive impairment (≤-2 standard deviation [SD] deviation after adjustment for demographics) was identified in 12.4% of participants. In cognitively unimpaired (CU) individuals, age-specific thresholds targeting a PPV of 0.7 yielded an overall p-tau217 positivity rate of 11.8%, increasing from 3.5% (< 60 years) to 6.3% (60-70 years) and 25.9% (≥70 years). Among cognitively impaired (CI) participants, 26.6% were p-tau217 positive. DISCUSSION: This framework supports practical integration of plasma biomarkers into community-based screening, with longitudinal follow-up needed to further refine threshold selection. HIGHLIGHTS: Regression-based residual method reduced education bias, identifying 12.4% with cognitive impairment individuals. Fully automated chemiluminescent assay enabled practical, large-scale biomarker implementation. Brief screening strategy supports early detection, clinical trial recruitment, and resource allocation in under-resourced regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.